Fulvestrant/AI is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Fudan University (1), Qilu Pharmaceutical Co., Ltd. (1) and Zhimin Shao (1). Registered phases: Phase 2, Phase 1/2 and Phase 3. Conditions studied include Breast Cancer Metastatic; Advanced ER+/HER2- Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05759546 | PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer Metastatic |
Phase 2 | Recruiting |
| NCT07235176 | Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients (ClinicalTrials.gov ↗) Advanced ER+/HER2- Breast Cancer |
Phase 1/2 | Recruiting |
| NCT06612814 | PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer Metastatic |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer Metastatic | 2 |
| Advanced ER+/HER2- Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 |
| Zhimin Shao | 1 |
| Register | Fulvestrant/AI trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fulvestrant/AI works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fulvestrant/AI (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.